ArticleViruses2023
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Characterization ofPHAGE (New Rochelle, N.Y.) · 2026Article
- Bacteriophages as Antibacterial Agents Against Bovine Pathobionts Associated with Foodborne Human Morbidity.Viruses · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, functional characterization and antibiofilm properties of a lytic Enterococcus phage RG1 against multidrug resistant E. faecium.Scientific reports · 2025Article
- Phage to ESKAPE: Personalizing Therapy for MDR Infections-A Comprehensive Clinical Review.Pathogens (Basel, Switzerland) · 2025Review
- Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.Antimicrobial agents and chemotherapy · 2025Review
- Characterization and therapeutic evaluation of the lytic bacteriophage ENP2309 against vancomycin-resistant Enterococcus faecalis infections in a mice model.Virology journal · 2025Article
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Dual Nature of Bacteriophages: Friends or Foes in Minimally Processed Food Products-A Comprehensive Review.Viruses · 2025Review
- Characterization and genomic analysis of aFrontiers in microbiology · 2025Article
- Bacteriophage Therapy as a Promising Alternative for Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- A novelFrontiers in microbiology · 2024Article
- A review and new perspective on oral bacteriophages: manifestations in the ecology of oral diseases.Journal of oral microbiology · 2024Review
- Review
- Enterococcal Phages: Food and Health Applications.Antibiotics (Basel, Switzerland) · 2023Review
- Bacteriolytic Potential ofViruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of antimicrobial resistant (AMR) bacteria is a major health concern, especially with regard to members of the ESKAPE group, to which vancomycin-resistant (VRE)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.